PMID- 22403483
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20220311
IS  - 1177-2719 (Electronic)
IS  - 1177-2719 (Linking)
VI  - 7
DP  - 2012
TI  - Detection of 1p19q deletion by real-time comparative quantitative PCR.
PG  - 9-17
LID - 10.4137/BMI.S9003 [doi]
AB  - 1p/19q (1p and/or 19q) deletions are prognostic factors in oligodendroglial 
      tumors (OT) and predict better survival after both chemotherapy and radiotherapy. 
      While studying 1p/19q status as a potential variable within multivariate 
      prognosis models for OT, we have frequently encountered unknown 1p/19q status 
      within our glioma sample database due to lack of paired blood samples for loss of 
      heterozygosity (LOH) assay and/or failure to perform fluorescence in situ 
      hybridization (FISH). We realized that a 1p and 19q deletion assay that could be 
      reliably performed solely on tumor DNA samples would allow us to fill in these 
      molecular biology data "holes". We built recombinant DNA with fragments of the 
      selected "marker" genes in 1p (E2F2, NOTCH2), and 19q (PLAUR) and "reference" 
      genes (ERC2, SPOCK1, and SPAG16 ) and used it as quantification standard in 
      real-time PCR to gain absolute ratios of marker/reference gene copy numbers in 
      tumor DNA samples, thus called comparative quantitative PCR (CQ-PCR). Using 
      CQ-PCR, we identified 1p and/ or 19q deletions in majority of pure low-grade 
      oligodenroglioma (OG) tumors (17/21, 81%), a large portion of anaplastic 
      oligodendroglioma (AO) tumors (6/15, 47%), but rarely found in mixed 
      oligoastrcytomas (OA) tumors (1/8, 13%). These data are consistent with results 
      of LOH and FISH assays generally reported for these tumor types. In addition, 15 
      out 18 samples showed concordant results between FISH and CQ-PCR. We conclude 
      that CQ-PCR is a potential means to gain 1p/19q deletion information, which 
      prognostic and predictive values of CQ-PCR-derived 1p/19q status will be 
      determined in a future study.
FAU - Chaturbedi, Abhishek
AU  - Chaturbedi A
AD  - Department of Neurological Surgery, University of California, Irvine, CA.
FAU - Yu, Liping
AU  - Yu L
FAU - Linskey, Mark E
AU  - Linskey ME
FAU - Zhou, Yi-Hong
AU  - Zhou YH
LA  - eng
PT  - Journal Article
DEP - 20120201
PL  - United States
TA  - Biomark Insights
JT  - Biomarker insights
JID - 101288638
PMC - PMC3290106
OTO - NOTNLM
OT  - 1p19q deletion
OT  - glioblastoma multiforme
OT  - glioma
OT  - oligodendroglial tumors
OT  - real-time comparative quantitative PCR
EDAT- 2012/03/10 06:00
MHDA- 2012/03/10 06:01
PMCR- 2012/02/01
CRDT- 2012/03/10 06:00
PHST- 2012/03/10 06:00 [entrez]
PHST- 2012/03/10 06:00 [pubmed]
PHST- 2012/03/10 06:01 [medline]
PHST- 2012/02/01 00:00 [pmc-release]
AID - bmi-7-2012-009 [pii]
AID - 10.4137/BMI.S9003 [doi]
PST - ppublish
SO  - Biomark Insights. 2012;7:9-17. doi: 10.4137/BMI.S9003. Epub 2012 Feb 1.